SuperworthGain Therapeutics EPS GANX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.51
- Latest quarter, Q2 FY26
- −$0.11
- Fiscal year 2025
- −$0.62
Gain Therapeutics' earnings per share was −$0.51 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.11.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.62 | n/a |
| FY2024 | −$0.95 | n/a |
| FY2023 | −$1.73 | n/a |
| FY2022 | −$1.48 | n/a |
| FY2021 | −$1.46 | n/a |
| FY2020 | −$1.28 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.11 | n/a | −$0.51 | |
| Q1 FY26 | −$0.13 | n/a | −$0.59 | |
| Q4 FY25 | −$0.12 | n/a | −$0.62 | |
| Q3 FY25 | −$0.15 | n/a | −$0.64 | |
| Q2 FY25 | −$0.19 | n/a | −$0.66 | |
| Q1 FY25 | −$0.16 | n/a | −$0.89 | |
| Q4 FY24 | −$0.14 | n/a | −$0.95 | |
| Q3 FY24 | −$0.17 | n/a | −$1.12 | |
| Q2 FY24 | −$0.42 | n/a | −$1.32 | |
| Q1 FY24 | −$0.22 | n/a | −$1.52 | |
| Q4 FY23 | −$0.31 | n/a | −$1.73 | |
| Q3 FY23 | −$0.37 | n/a | −$1.81 |
Against its peers
Companies in Drug Manufacturers - General nearest Gain Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GANXGain Therapeutics | −$0.51 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Gain Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.